Pharming Group N.V. will host a webcast on June 30, 2025, to discuss findings from a study on diagnosing activated phosphoinositide 3-kinase delta syndrome (APDS), highlighting that over 1,300 U.S. patients have a variant of uncertain significance. The research may indicate a higher prevalence of APDS than previously thought.